Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| GMP-FGCH17 | Human | GMP Human FGF basic Protein |  |
|
|
| BFF-H5115 | Human | Human FGF basic (154aa) Protein, premium grade |  |
|
|
| FGC-H81E3 | Human | Biotinylated Human FGF basic Protein, Avitag™,His Tag (MALS verified) |  |
|
|
| BFF-H4117 | Human | Human FGF basic Protein, premium grade |  |
|
|
GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) stimulates proliferation of NIH/3T3 cells. The specific activity of GMP Human FGF basic Protein is >2.50 x 10^6 IU/mg, which is calibrated against Basic Fibroblast Growth Factor WHO International Standard (NIBSC code: 90/712) (QC tested).
Human FGF basic, premium grade (Cat. No. BFF-H4117) stimulates proliferation of NIH/3T3 cells. The specific activity of Human FGF basic, premium grade is >2.5 x 10^6 IU/mg, which is calibrated against human FGF basic WHO International Standard (NIBSC code: 90/712) (QC tested).
Immobilized Human Glypican 3, Fc Tag, low endotoxin (Cat. No. GP3-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Avitag,His Tag (Cat. No. FGC-H81E3) with a linear range of 0.6-10 ng/mL (QC tested).
The purity of Human FGF basic (154aa) Protein, premium grade (Cat. No. BFF-H5115) is more than 90% and the molecular weight of this protein is around 15-25 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Lymphoma, Mantle-Cell; Leprosy, Lepromatous; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Carcinoma, Adenosquamous; Cholangitis, Sclerosing; Osteosarcoma; Endometrial Neoplasms; Xerostomia; Gastrointestinal Hemorrhage; Sarcoma, Ewing; HIV Wasting Syndrome; Pancreatitis, Chronic; Arachnoiditis; Retinoblastoma; Erythema Nodosum; Prostatic Neoplasms; Drug Resistant Epilepsy; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Sarcoma; Angiodysplasia; Lymphoma, Non-Hodgkin; Appendiceal Neoplasms; Pelvic Pain; Waldenstrom Macroglobulinemia; Glioma; Uterine Neoplasms; Anemia, Sideroblastic; Lung Neoplasms; Mycobacterium Infections; Lupus Erythematosus, Discoid; Anemia, Refractory, with Excess of | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RBM-007 | ID3 (21); APT-F2; RBM-007 | Phase 2 Clinical | Ribomic | Achondroplasia; Macular Degeneration | Details |
| Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Solid tumours; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Fibroblast growth factor 2 gene therapy (ID Pharma) | SeV-10101; SEV-10101; DVC-10101; BF-30 | Phase 2 Clinical | Dnavec | Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease; Peripheral arterial occlusive disorders | Details |
This web search service is supported by Google Inc.
A-Z
